Gustavo Schvartsman

Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer

BackgroundPatients with extensive-stage small-cell lung cancer have poor outcomes, with a median overall survival of approximately 12 to 13 months. Tarlatamab (a bispecific T-cell engager targeting delta-like ligand 3 [DLL3] and CD3) was previously shown to improve survival as se...